中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.023 seconds)

    COMPOSITION FOR MODULATING IRAK1
    2.
    发明申请
    COMPOSITION FOR MODULATING IRAK1 审中-公开

    公开(公告)号：US20180311264A1

    公开(公告)日：2018-11-01

    申请号：US15770437

    申请日：2016-10-24

    Applicant: Agency for Science,Technology and Research

    Inventor： Qiang Yu ,  Zhen Ning Wee

    IPC: A61K31/704 ,  A61P35/00 ,  C12Q1/6886

    CPC classification number: A61K31/704 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2800/52

    Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.

    Composition for modulating IRAK1
    4.
    发明授权
    Composition for modulating IRAK1 有权

    公开(公告)号：US10881677B2

    公开(公告)日：2021-01-05

    申请号：US15770437

    申请日：2016-10-24

    Applicant: Agency for Science, Technology and Research

    Inventor： Qiang Yu ,  Zhen Ning Wee

    IPC: A61K31/704 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

    Abstract: The present invention relates to the treatment of breast cancer, more particularly triple negative breast cancer (TNBC), with the use of an inhibitor of Interleukin 1 Receptor Associated Kinase 1 (IRAK1) such as ginsenosides. It also relates to a method for aiding in categorising or determining prognosis in a breast cancer patient or in selecting a therapeutic strategy comprising assessing the level of IRAK1 nucleic acid, protein or activity in a sample and, in some aspects, further assessing the paclitaxel resistance status of the patient and if the patient is resistant to paclitaxel therapy, treating the patient with an inhibitor of IRAK1 activity. In addition, a screening method for identifying a compound useful for treating breast cancer comprises determining the effect of a test compound on IRAK1 nucleic acid, protein or activity level and selecting a compound that reduces said level.

    Method of identifying risk of cancer and therapeutic options
    7.
    发明授权
    Method of identifying risk of cancer and therapeutic options 有权

    公开(公告)号：US11680298B2

    公开(公告)日：2023-06-20

    申请号：US16331072

    申请日：2017-09-07

    Applicant: Agency for Science, Technology and Research ,  Tan Tock Seng Hospital Pte. Ltd.

    Inventor： Qiang Yu ,  Jian Yuan Goh ,  Min Feng ,  Ern Yu Tan

    IPC: C12Q1/68 ,  C12Q1/6886 ,  A61K31/519

    CPC classification number: C12Q1/6886 ,  A61K31/519 ,  C12Q2600/112 ,  C12Q2600/156

    Abstract: There is provided a method of identifying risk of cancer in a human subject, the method comprising: determining in a biological sample of the subject, whether a copy number amplification of at least one continuous genomic region specific to human chromosome 1q21 is present, wherein the presence of a copy number amplification of the region specific to human chromosome 1q21 represents an elevated risk of cancer in the subject and the at least one continuous genomic region is selected from the group consisting of: a human TUFT 1 gene or a gene from the human S100 family. It is also provided a method of treating cancer in a subject determined to have a copy number amplification of a region specific to human chromosome 1q21, the method comprising administering a therapeutic agent capable of suppressing IRAK1, IRAK4 or a S100 family member, such as Pacritinib. There are also provided a method of treating cancer, related polynucleotides, kits, therapeutic agents and use of the therapeutic agents.

Patent Agency Ranking